Professor Alasdair Coles - Publications

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

01 Sep 2017

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

01 Jan 2019

Keratinocyte growth factor impairs human thymic recovery from lymphopenia

01 May 2019

Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury

18 Jun 2021

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

01 Sep 2021

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

09 Dec 2021

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

19 May 2022

The impact of smoking cessation on multiple sclerosis disease progression

24 May 2022

Remyelination varies between and within lesions in multiple sclerosis following bexarotene

17 Sep 2022